AstraZeneca files Crestor/TriLipix combination
This article was originally published in Scrip
AstraZeneca and Abbott have filed a US NDA for Certriad, a combination of AstraZeneca's Crestor (rosuvastatin calcium) and Abbott's TriLipix (fenofibric acid), for the treatment of mixed dyslipidaemia. The two firms have also entered into a co-promotion agreement for TriLipix, further strengthening the ties between them in the cardiovascular area – they already have an agreement whereby Abbott co-promotes Crestor in the US.
You may also be interested in...
The leading PARP inhibitor gets a new tumor type added to its label after a narrow ODAC vote in favor less than a fortnight ago.
Andrew McConaghie and Alex Shimmings are joined by John Hawkins, biographer of biotech pioneer Henri Termeer, and Idea Pharma's Mike Rea to pick out their personal book highlights of 2019.
Concerns that written interventions might delay the expected EU approval of the novel ketamine-based antidepressant have come to naught.